Roche Faces Critical Week with MS Drug Data and Q1 Report
Roche stock faces pivotal week with Phase III MS drug safety data on April 22 and Q1 sales…
Roche Faces Critical Week with MS Drug Data and Q1 Report
Roche stock faces pivotal week with Phase III MS drug safety data on April 22 and Q1 sales…
Roche Shares Under Pressure Following Clinical Trial Setback
Roche shares drop after giredestrant fails Phase III breast cancer trial. Analysts diverge on outlook as company pivots…
Roche’s Dividend Milestone Overshadowed by Clinical Trial Setback
Roche’s 39th consecutive dividend increase contrasts with a Phase III trial failure for giredestrant, pressuring shares and clouding…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer](https://www.europesays.com/ch/wp-content/uploads/2026/03/964824-380x220.png)
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival,…
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4,…
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1…
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
In ALIGN study, Vanrafia (atrasentan) showed positive differencein eGFR change from baseline vs. placebo at Week 136, 4…